Insilico Medicine receives soft takeover approaches – CEO
- Does not have defense advisor in place
- Considers itself an attractive takeover target in AI drug discovery
- Secondary listing in Abu Dhabi likely to go ahead
AI-driven drug discovery company Insilico Medicine has received soft takeover enquiries and interest from potential buyers, founder, CEO and chairman Alex Zhavoronkov said.
“We’re not in serious talks right now, but people are actively looking and enquiring,” Zhavoronkov told this news service on the sidelines of the Financial Times Global Pharma and Biotech Summit in London this week.
The CEO said management has not brought any such enquiries to the board so far and has not appointed an adviser to handle enquiries or defend against a takeover.
The Hong Kong-listed company, with dual headquarters in Boston and Hong Kong, considers itself “the most attractive takeover target in the field of AI drug discovery”, also due to the large number of therapeutic assets in its drug pipeline, Zhavoronkov said.
A lot of players would like to own Insilico to really get into AI-driven drug discovery and gain this expertise, he said.
“Ask any LLM – we are the largest AI-driven drug discovery company in the world,” Zhavoronkov said. “Gemini would wrongly say it’s Isomorphic Labs because they’ve raised the most capital. But if you go dollar for dollar, we’re the most efficient.”
Insilico Medicine has a market cap of HKD 23.2bn (USD 2.96bn).
The CEO said he would prefer for Insilico not to be taken over but has limited power in potential takeover situations. Even as the largest shareholder, he only holds 7% of shares, while for most shareholders it would simply be a matter of price, he added.
“If it’s a frontier lab that really understands how to do it, there’s no way we can defend”, he said.
Secondary listing plans
Insilico listed on the Hong Kong Stock Exchange in December 2025. In May this year, it was reported that the company was considering a secondary listing in Abu Dhabi.
Zhavoronkov said a secondary listing is likely to go ahead, “probably sooner rather than later”, without giving more update.
When asked about the reason for listing in Abu Dhabi specifically, he said the company has 60 scientists in the UAE, and some of its therapeutic assets are being developed there.
Insilico is not planning to raise capital in connection with a potential secondary listing, as it has close to USD 1bn in cash, according to the CEO.
According to its latest available financial report, Insilico had cash and cash equivalents of USD 358m at the end of June 2026.
Licensing deals
Insilico has a large pipeline of drug candidates for conditions including fibrosis, cancer, pain, obesity, and inflammatory diseases. The company’s model is to out-license its assets, and it has done nine licensing and collaboration deals so far this year, the CEO said.
Insilico’s flagship asset is a therapy for idiopathic pulmonary fibrosis (IPF), currently in Phase III clinical trials, for which the company wants to keep global rights, Zhavoronkov said. For all other assets in the pipeline not already out-licensed, the company is interested in signing licensing deals, he said.
Insilico also has collaborations with major pharmaceutical companies that use its Pharma.AI platform to accelerate drug research and discovery.
Its competitors are 100% Chinese such as Jiangsu Hengrui, Jiangsu Hansoh, Qilu Pharmaceutical, Fosun Pharma, and CSPC Pharmaceutical Group, Zhavoronkov said.